Tumor histoculture captures the dynamic interactions between tumor and immune components in response to anti-PD1 in head and neck cancer.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
21 Feb 2024
21 Feb 2024
Historique:
received:
24
05
2023
accepted:
02
02
2024
medline:
22
2
2024
pubmed:
22
2
2024
entrez:
21
2
2024
Statut:
epublish
Résumé
Dynamic interactions within the tumor micro-environment drive patient response to immune checkpoint inhibitors. Existing preclinical models lack true representation of this complexity. Using a Head and Neck cancer patient derived TruTumor histoculture platform, the response spectrum of 70 patients to anti-PD1 treatment is investigated in this study. With a subset of 55 patient samples, multiple assays to characterize T-cell reinvigoration and tumor cytotoxicity are performed. Based on levels of these two response parameters, patients are stratified into five sub-cohorts, with the best responder and non-responder sub-cohorts falling at extreme ends of the spectrum. The responder sub-cohort exhibits high T-cell reinvigoration, high tumor cytotoxicity with T-cells homing into the tumor upon treatment whereas immune suppression and tumor progression pathways are pre-dominant in the non-responders. Some moderate responders benefit from combination of anti-CTLA4 with anti-PD1, which is evident from better cytotoxic T-cell: T-regulatory cell ratio and enhancement of tumor cytotoxicity. Baseline and on-treatment gene expression signatures from this study stratify responders and non-responders in unrelated clinical datasets.
Identifiants
pubmed: 38383563
doi: 10.1038/s41467-024-45723-z
pii: 10.1038/s41467-024-45723-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1585Informations de copyright
© 2024. The Author(s).
Références
Zhang, N. & Bevan, M. J. CD8+ T cells: foot soldiers of the immune system. Immunity 35, 161–168 (2011).
doi: 10.1016/j.immuni.2011.07.010
pubmed: 21867926
pmcid: 3303224
Philip, M. & Schietinger, A. CD8+ T cell differentiation and dysfunction in cancer. Nat. Rev. Immunol. 22, 209–223 (2022).
doi: 10.1038/s41577-021-00574-3
pubmed: 34253904
Robert, C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat. Commun. 11, 3801 (2020).
Farhood, B., Najafi, M. & Mortezaee, K. CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review. J. Cell. Physiol. 234, 8509–8521 (2019).
doi: 10.1002/jcp.27782
pubmed: 30520029
Zhao, F. et al. Stromal fibroblasts mediate anti–PD-1 resistance via MMP-9 and dictate TGFb inhibitor sequencing in melanoma. Cancer Immunol. Res 6, 1459–1471 (2018).
doi: 10.1158/2326-6066.CIR-18-0086
pubmed: 30209062
pmcid: 6279598
Hinshaw, D. C. & Shevde, L. A. The tumor microenvironment innately modulates cancer progression. Cancer Res. 79, 4557–4567 (2019).
doi: 10.1158/0008-5472.CAN-18-3962
pubmed: 31350295
pmcid: 6744958
Powley, I. R. et al. Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery. Br. J. Cancer 122, 735–744 (2020).
doi: 10.1038/s41416-019-0672-6
pubmed: 31894140
pmcid: 7078311
Runge, A. et al. Patient-derived head and neck tumor slice cultures: a versatile tool to study oncolytic virus action. Sci. Rep. 12, 15334 (2022).
doi: 10.1038/s41598-022-19555-0
pubmed: 36097280
pmcid: 9467994
Voabil, P. et al. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nat. Med 27, 1250–1261 (2021).
doi: 10.1038/s41591-021-01398-3
pubmed: 34239134
Chen, J. et al. Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer. Signal Transduct. Target Ther. 6, 4 (2021).
doi: 10.1038/s41392-020-00377-3
pubmed: 33414378
pmcid: 7791142
Jorgovanovic, D., Song, M., Wang, L. & Zhang, Y. Roles of IFN-γ in tumor progression and regression: a review. Biomark. Res 8, 49 (2020).
doi: 10.1186/s40364-020-00228-x
pubmed: 33005420
pmcid: 7526126
Voskoboinik, I., Whisstock, J. C. & Trapani, J. A. Perforin and granzymes: Function, dysfunction and human pathology. Nat. Rev. Immunol. 15, 388–400 (2015).
doi: 10.1038/nri3839
pubmed: 25998963
Tokunaga, R. et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy. Cancer Treat. Rev. 63, 40–47 (2018).
doi: 10.1016/j.ctrv.2017.11.007
pubmed: 29207310
Ayers, M. et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Investig. 127, 2930–2940 (2017).
doi: 10.1172/JCI91190
pubmed: 28650338
pmcid: 5531419
Rettig, E., Kiess, A. P. & Fakhry, C. The role of sexual behavior in head and neck cancer: implications for prevention and therapy. Expert Rev. Anticancer Ther. 15, 35–49 (2014).
doi: 10.1586/14737140.2015.957189
pubmed: 25193346
pmcid: 4385715
Chauhan, R., Trivedi, V., Rani, R. & Singh, U. A study of head and neck cancer patients with reference to tobacco use, gender, and subsite distribution. South Asian J. Cancer 11, 046–051 (2022).
doi: 10.1055/s-0041-1740601
Yi, M. et al. TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy. Front. Immunol. 13, 1061394 (2022).
Meurette, O. & Mehlen, P. Notch signaling in the tumor microenvironment. Cancer Cell 34, 536–548 (2018).
doi: 10.1016/j.ccell.2018.07.009
pubmed: 30146333
Foy, S. P. et al. Non-viral precision T cell receptor replacement for personalized cell therapy. Nature 615, 687–696 (2023).
doi: 10.1038/s41586-022-05531-1
pubmed: 36356599
Chen, P. L. et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 6, 827–837 (2016).
doi: 10.1158/2159-8290.CD-15-1545
pubmed: 27301722
pmcid: 5082984
Fasano, M. et al. Immunotherapy for head and neck cancer: Present and future. Critic. Rev. Oncology/Hematology 174, 103679 (2022).
Goodman, A. M. et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther. 16, 2598–2608 (2017).
doi: 10.1158/1535-7163.MCT-17-0386
pubmed: 28835386
pmcid: 5670009
Lei, Q., Wang, D., Sun, K., Wang, L. & Zhang, Y. Resistance mechanisms of anti-PD1/PDL1 therapy in solid tumors. Front. Cell Develop. Biol. 8, 672 (2020).
Callahan, M. K. & Wolchok, J. D. Recruit or reboot? how does anti-pd-1 therapy change tumor-infiltrating lymphocytes? Cancer Cell 36, 215–217 (2019).
doi: 10.1016/j.ccell.2019.08.009
pubmed: 31526757
Anagnostou, V. & Luke, J. J. Quantitative spatial profiling of tils as the next step beyond pd-l1 testing for immune checkpoint blockade. Clin. Cancer Res. 28, 4835–4837 (2022).
doi: 10.1158/1078-0432.CCR-22-2277
pubmed: 36103258
pmcid: 9669208
Hammerl, D. et al. Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. Nat. Commun. 12, 5668 (2021).
doi: 10.1038/s41467-021-25962-0
pubmed: 34580291
pmcid: 8476574
DeVito, N. C. et al. Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy. Cell Rep. 35, 109071 (2021).
doi: 10.1016/j.celrep.2021.109071
pubmed: 33951424
pmcid: 8148423
Javed, Z. et al. Wnt signaling: A potential therapeutic target in head and neck squamous cell carcinoma. Asian Pac. J. Cancer Prev. 20, 995–1003 (2019).
doi: 10.31557/APJCP.2019.20.4.995
pubmed: 31030466
pmcid: 6948882
Jung, Y.-S., Jun, S., Lee, S. H., Sharma, A. & Park, J.-I. Wnt2 complements Wnt/β-catenin signaling in colorectal cancer. vol. 6 www.impactjournals.com/oncotarget .
Unterleuthner, D. et al. Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer. Angiogenesis 23, 159–177 (2020).
doi: 10.1007/s10456-019-09688-8
pubmed: 31667643
Jiang, H. et al. Activation of the Wnt pathway through Wnt2 promotes metastasis in pancreatic cancer. Am. J. Cancer Res. 4 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4163618/ (2014).
Katoh, M. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). Int. J. Oncol. 51, 1357–1369 (2017).
doi: 10.3892/ijo.2017.4129
pubmed: 29048660
pmcid: 5642388
Yi, M. et al. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol. Cancer 21, 28 (2022).
Wu, C. C., Wang, Y. A., Livingston, J. A., Zhang, J. & Futreal, P. A. Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association. Nat. Commun. 13, 42 (2022).
doi: 10.1038/s41467-021-27651-4
pubmed: 35013211
pmcid: 8748689
W. H. O. Classification of tumours editorial board. WHO classification of tumours series. Head and neck tumours. 5th ed., Vol. 9 (International Agency for Research on Cancer, Lyon, 2022).
Bankhead, P. et al. QuPath: Open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).
doi: 10.1038/s41598-017-17204-5
pubmed: 29203879
pmcid: 5715110
Erhart, S. M. M., Rivero, E. R. C., Bazzo, M. L. & Onofre, A. S. C. Comparative evaluation of the GP5+/6+, MY09/11 and PGMY09/11 primer sets for HPV detection by PCR in oral squamous cell carcinomas. Exp. Mol. Pathol. 100, 13–16 (2016).
doi: 10.1016/j.yexmp.2015.11.024
pubmed: 26621496
Van Der Maaten, L. & Hinton, G. Visualizing Data using t-SNE. J. Mach. Learn. Res. 9, https://www.jmlr.org/papers/volume9/vandermaaten08a/vandermaaten08a.pdf (2008).
Foy, J.-P. et al. Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitors. Data Brief. 44, 108556 (2022).
doi: 10.1016/j.dib.2022.108556
pubmed: 36111282
pmcid: 9467865